Squarepoint
VIR icon

Squarepoint’s Vir Biotechnology VIR Stock Holding History

Squarepoint’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,500
Closed -$385K – 5476
2024
Q4 		$385K Hold
52,500
– – ﹤0.01% 3957
2024
Q3 		$393K Sell
52,500
-49,400
-48% -$429K ﹤0.01% 3277
2024
Q2 		$907K Buy
+101,900
New +$977K ﹤0.01% 2633

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Squarepoint's VIR Position: Q2 2026 in Review

Squarepoint increased its Vir Biotechnology (VIR) stake by 385% in Q2 2026, buying an estimated $953K and bringing the position to 126,141 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2706.

Squarepoint first reported a position in VIR in Q4 2019 and has held it in 16 quarters since. The position peaked at $3.07M in Q1 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Squarepoint held 126,141 shares of Vir Biotechnology worth $1.29M as of Q2 2026.
  • Squarepoint bought 100,128 Vir Biotechnology shares in Q2 2026, an estimated $953K.
  • Vir Biotechnology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2706 holding.
  • Squarepoint first reported a position in Vir Biotechnology in Q4 2019 and has held it in 16 quarters since.
  • Squarepoint's Vir Biotechnology position peaked at $3.07M in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.